Cutaneous lupus patients saw erythema clearance climb to 27.2% at one year on investigational litifilimab, HCPLive reported, with no serious viral infections in the 52-week AMETHYST Part A extension.
The rising response curve — from 19.0% at week 24 — mirrors the delayed-but-durable pattern seen with upstream interleukin-23 blockade in psoriasis, investigators noted at the European Academy of Dermatology and Venereology Congress in Vienna this autumn. Litifilimab targets blood dendritic cell antigen 2 (BDCA2) on plasmacytoid dendritic cells, choking off type I interferon production before it reaches skin tissue.
Litifilimab Shows Sustained Skin Clearance over a Year
- Litifilimab is an experimental biologic that quiets the immune cells driving skin lupus, offering a potential steroid-sparing alternative to current mainstays.
- Skin clearance rates improved steadily over a full year, suggesting the drug keeps working longer rather than fading.
- Because most cutaneous lupus never becomes systemic, dermatologists are positioned to manage these patients long-term, calling rheumatology only for specific red flags.
Antibody Targets Plasmacytoid Dendritic Cells Upstream of Interferon
Litifilimab is a humanized monoclonal antibody that binds BDCA2 on plasmacytoid dendritic cells, suppressing type I interferon-alpha and -beta production upstream of the inflammatory cascade. Anifrolumab (Saphnelo), already approved for systemic lupus erythematosus, blocks the type I interferon receptor downstream instead.
The phase 2 AMETHYST Part A study enrolled patients with moderate-to-severe cutaneous lupus erythematosus refractory to antimalarials. The primary endpoint was the Cutaneous Lupus Erythematosus Investigator Global Activity–Revised (CLA-IGA-R) erythema score of 0 or 1.
Efficacy Deepens Over Time
At week 24, 19.0% of litifilimab recipients achieved the CLA-IGA-R erythema 0/1 threshold. That proportion rose to 27.2% by week 52 among patients who started the drug at baseline. Complete clearance of morphologic features beyond erythema increased from 14.2% to 20.8% over the same interval.
On the Clinician’s Global Assessment of Skin, 55.6% of treated patients were rated much or moderately better at week 24 versus 28.0% on placebo; patient-reported ratings showed 48.9% versus 29.6%. No serious viral infections were reported through 52 weeks.
| Measure | Week 24 | Week 52 |
|---|---|---|
| CLA-IGA-R Erythema 0/1 Response | 19.0% | 27.2% |
| Complete Morphologic Clearance | 14.2% | 20.8% |
| Clinician Global: Much/Moderately Better | 55.6% | — |
| Patient Global: Much/Moderately Better | 48.9% | — |
Dermatology Ownership and Rheumatology Triage
Roughly 80% of cutaneous lupus patients never progress to systemic disease, presenters argued, supporting dermatologist-led long-term management. Severity should be gauged by lesion extent, involvement of high-impact sites such as the face, scalp, and hands, scarring risk, and treatment resistance. Acute cutaneous lupus, renal warning signs, inflammatory musculoskeletal symptoms, new laboratory abnormalities, or failure of multiple therapies should trigger rheumatology referral.
Regulatory Horizon and Competitive Landscape
Phase 3 AMETHYST results are expected in the first half of 2027. The LAVENDER trial, evaluating anifrolumab in a similar refractory cutaneous population, will report on a comparable timeline. If both succeed, dermatology would gain two targeted, steroid-sparing options for a condition long managed with hydroxychloroquine and broad immunosuppressants such as methotrexate or mycophenolate mofetil. Funding for the AMETHYST program comes from Biogen, the sponsor of litifilimab development.
The European Academy of Dermatology and Venereology was founded as a non-profit association on 3rd October 1987 in Luxembourg, following a proposal by Danish Professor Hans Rothenburg. Prof Emiliano Panconesi became its first President and led the inaugural Congress in Florence in September 1989, which drew more than 3’000 participants.
Today the Academy counts over 15’000 members worldwide and operates as a platform for collaboration across borders and sub-specialties, with expert task forces shaping standards and best-practice guidelines.
Investigational Drug Requires Rheumatology Referral for Systemic Signs
Litifilimab remains investigational and is not approved by the FDA, EMA, or MHRA for any indication. Patients with active serious infections, untreated latent tuberculosis, or hypersensitivity to monoclonal antibody components should avoid enrollment in clinical trials. Anyone with cutaneous lupus experiencing new joint swelling, unexplained fever, proteinuria, or rapidly spreading skin lesions should seek immediate rheumatology evaluation regardless of current therapy.
References
- Merola JF, Werth V, Chong B, et al. 52-week findings from the phase 2 AMETHYST Part A trial on litifilimab efficacy and safety in cutaneous lupus erythematosus. Abstract AS-1846. Presented at: EADV Congress 2026; September 30–October 3, 2026; Vienna, Austria.
- Werth VP, Furie RA, Romero-Diaz J, et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. 2022;387(4):321-331. doi:10.1056/NEJMoa2118024
- Furie R, Werth VP, Milliman E, et al. In a randomized, placebo-controlled phase 2 trial, litifilimab produced rapid and sustained reductions in type I interferon-associated gene expression and cytokines in lupus. 2025;77(12):1726-1738. doi:10.1002/art.43271
- AMETHYST Part A clinician- and patient-rated skin outcomes with litifilimab. Abstract 0872. Presented at: ACR Convergence 2026; November 8, 2026.